65,437 trials
Disease, Hodgkin
Primary: Objective Response Rate by Independent Review Group — 75 percent of participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 1.189…
Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Independent Review Group — 86 percent of participants
Leukemia
Primary: Confirmed Response, Defined as Objective Complete Remission or Partial Remission for a Duration of at Least 2 Months — 27 participants
Infections, Papillomavirus
Primary: Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18 — 0; 5; 0; 4 subjects
End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: Evaluation of Area Under the Curve From Time 0 to Infinity — 1692; 2708 hr*ug/mL
Seizures
Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…
Secondary Hyperparathyroidism · Dialysis
Primary: Proportion of Subjects Who Achieve at Least a 50% Reduction in iPTH Compared to Baseline Level — 17; 57 participants
Heart Catheterization
Primary: Percentage of Participants Who Require Anticoagulation and/or Have Clinical Signs of Catheter Related Thrombosis — 10.5; 14.3; 10.0 Percentage of participants
Asthma
Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 3.94…
Bipolar Disorder · Depression, Bipolar
Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01
Colonoscopy
Primary: Number of Patients Undergoing Complete Unsedated Colonoscopy — 101; 89 participants
Rheumatoid Arthritis
Primary: Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product…
Epilepsy, Partial
Primary: Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase — 51.6; 67.9 percentage of participants
Staphylococcal Sepsis
Primary: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35. — 85; 79 Participants